{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:49:39Z","timestamp":1760986179096},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,31]]},"DOI":"10.7759\/cureus.34467","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T21:01:10Z","timestamp":1675198870000},"source":"Crossref","is-referenced-by-count":3,"title":["A Case Report on Metamizole-Induced Agranulocytosis: Is the Benefit Worth the Risk?"],"prefix":"10.7759","author":[{"given":"Rita","family":"Carvalho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9lia","family":"Henriques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udio","family":"Gouveia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Gama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1781-z","article-title":"Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports","volume":"71","author":"Blaser LS","year":"2015","unstructured":"Blaser LS, Tramonti A, Egger P, Haschke M, Kr\u00e4henb\u00fchl S, R\u00e4tz Bravo AE. Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports. Eur J Clin Pharmacol. 2015, 71:209-217. 10.1007\/s00228-014-1781-z","journal-title":"Eur J Clin Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1777-8","article-title":"Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case-Control Surveillance Study","volume":"71","author":"Huber M","year":"2015","unstructured":"Huber M, Andersohn F, Sarganas G, et al.. Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol. 2015, 71:219-227. 10.1007\/s00228-014-1777-8","journal-title":"Eur J Clin Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1895-y","article-title":"Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990-2012","volume":"71","author":"Stammschulte T","year":"2015","unstructured":"Stammschulte T, Ludwig WD, M\u00fchlbauer B, Bronder E, Gundert-Remy U. Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990-2012. Eur J Clin Pharmacol. 2015, 71:1129-1138. 10.1007\/s00228-015-1895-y","journal-title":"Eur J Clin Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2017.14438","article-title":"Leucopenia associated with metamizole: a case-control study","volume":"147","author":"Blaser L","year":"2017","unstructured":"Blaser L, Hassna H, Hofmann S, et al.. Leucopenia associated with metamizole: a case-control study. Swiss Med Wkly. 2017, 147:w14438. 10.4414\/smw.2017.14438","journal-title":"Swiss Med Wkly"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13310","article-title":"Agranulocytosis attributed to metamizole: an analysis of spontaneous reports in EudraVigilance 1985-2017","volume":"126","author":"Hoffmann F","year":"2020","unstructured":"Hoffmann F, Bantel C, Jobski K. Agranulocytosis attributed to metamizole: an analysis of spontaneous reports in EudraVigilance 1985-2017. Basic Clin Pharmacol Toxicol. 2020, 126:116-125. 10.1111\/bcpt.13310","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref6","unstructured":"Circular Informativa N.\u00ba 158\/CD\/550.20.001. Metamizol e risco de agranulocitose. (2018). Accessed: January 16, 2023: https:\/\/www.infarmed.pt\/documents\/15786\/2409571\/Metamizol+e+risco+de+agranulocitose\/b235fc4d-7768-4a3f-9eb4-28b1c8a6e...."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0836-y","article-title":"Agranulocytosis associated with dipyrone (metamizol)","volume":"60","author":"Ib\u00e1\u00f1ez L","year":"2005","unstructured":"Ib\u00e1\u00f1ez L, Vidal X, Ballar\u00edn E, Laporte JR. Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol. 2005, 60:821-829. 10.1007\/s00228-004-0836-y","journal-title":"Eur J Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-019-01774-4","article-title":"Metamizole and the risk of drug-induced agranulocytosis and neutropenia in statutory health insurance data","volume":"393","author":"Klose S","year":"2020","unstructured":"Klose S, Pflock R, K\u00f6nig IR, Linder R, Schwaninger M. Metamizole and the risk of drug-induced agranulocytosis and neutropenia in statutory health insurance data. Naunyn Schmiedebergs Arch Pharmacol. 2020, 393:681-690. 10.1007\/s00210-019-01774-4","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0465-2","article-title":"Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole)","volume":"58","author":"Hedenmalm K","year":"2002","unstructured":"Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol. 2002, 58:265-274. 10.1007\/s00228-002-0465-2","journal-title":"Eur J Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/pds.697","article-title":"Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis","volume":"11","author":"B\u00e4ckstr\u00f6m M","year":"2002","unstructured":"B\u00e4ckstr\u00f6m M, H\u00e4gg S, Mj\u00f6rndal T, Dahlqvist R. Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis. Pharmacoepidemiol Drug Saf. 2002, 11:239-245. 10.1002\/pds.697","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00482-016-0160-3","article-title":"[Dipyrone (metamizole): considerations on monitoring for early detection of agranulocytosis]","volume":"31","author":"Stamer UM","year":"2017","unstructured":"Stamer UM, Gundert-Remy U, Biermann E, Erlenwein J, Mei\u03b2ner W, Wirz S, Stammschulte T. [Dipyrone (metamizole): considerations on monitoring for early detection of agranulocytosis]. Schmerz. 2017, 31:5-13. 10.1007\/s00482-016-0160-3","journal-title":"Schmerz"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/135326-a-case-report-on-metamizole-induced-agranulocytosis-is-the-benefit-worth-the-risk","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:51:19Z","timestamp":1707508279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/135326-a-case-report-on-metamizole-induced-agranulocytosis-is-the-benefit-worth-the-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.34467","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,31]]}}}